Safety of Xeloda in Solid Tumours
The primary objective of this study is to observe safety and tolerability of Xeloda as used in medical practice, alone and in combination with docetaxel.
Metastatic Breast Cancer, Colon Cancer
DRUG: Docetaxel|DRUG: Xeloda
Number of Participants with Adverse Events, within 18 months
Disease free survival (DFS), within 18 months
The primary objective of this study is to observe safety and tolerability of Xeloda as used in medical practice, alone and in combination with docetaxel.